hotspot
As Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage results of its heart drug, CEO Robert Blum maintains that the biotech can launch the treatment — what would be its first approved medication — on its own.
Cytokinetics reported top-line results of its drug, aficamten, in obstructive hypertrophic cardiomyopathy, or oHCM, last December, sending its shares up on speculation the company would get acquired. Full Phase 3 results released this week further suggest the drug could be used more flexibly than a similar treatment sold by Bristol Myers Squibb, but investors have questioned whether the biotech has the resources and salesforce to compete with a large pharma company.
advertisement
Blum, speaking Thursday at a talk during STAT’s Breakthrough Summit West, said that if prospective buyers approach the company, he will talk to them, but “at the same time, we’re pushing forward, as we always have, with the original intention to build a commercial business. And that’s not something new. That’s not something that’s a result of a failed M&A dialogue.”
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
Monthly
$39
Totals $468 per year
$39/month Get StartedTotals $468 per year
Starter
$30
for 3 months, then $39/month
$30 for 3 months Get StartedThen $39/month
Annual
$399
Save 15%
$399/year Get StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/year Get Started$300 Annually per user
View All Plans
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
